Fly News Breaks for February 20, 2020
Feb 20, 2020 | 06:44 EDT
Citi analyst Yigal Nochomovitz says Reata Pharmaceuticals remains his top pick for 2020 with a Buy rating and $328 price target. The analyst expects approvals for both bardoxolone methyl in Alport syndrome and omaveloxolone in Friedreich's Ataxia. New Drug Application submissions for both are expected in 2020, Nochomovitz tells investors in a research note.
News For RETA From the Last 2 Days
There are no results for your query RETA